Form S-1
For each of the shares and warrants being registered for resale, disclose the price that the selling securityholders paid for such shares, warrants, or units overlying such securities.
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on the cover page and page 45 of Amendment No. 1 to disclose the purchase price paid by various selling securityholders for such shares and warrants.Read in the reply
Disclose the likelihood that warrant holders will not exercise their warrants. Provide similar disclosure in the prospectus summary, risk factors, MD&A and use of proceeds section and disclose that cash proceeds associated with the exercises of the warrants are dependent on the stock price.Rest of the question
Describe the impact on your liquidity and update the discussion on the ability of your company to fund your operations on a prospective basis with your current cash on hand.
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on the cover page and pages 14, 50, 53 and 62 ofRead in the reply
Amendment No. 1 to disclose that the cash proceeds associated with the exercise of the warrants are dependent on the stock price and also to describe any impact on our liquidity.
We note the significant number of redemptions of your common stock in connection with your business combination and that the shares being registered for resale will constitute a considerable percentage of your public float. Highlight the significant negative impact sales of shares on this registration statement could have on the public trading price of the common stock.Rest of the question
In this regard, highlight that certain of the shares being registered for resale were purchased by the selling securityholders for prices below the current market price of the common stock and that such securityholders would have an incentive to sell.
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on the cover page and pages 10, 19, 45-46 and 62-63 of Amendment No. 1 to disclose that the securities being registered for resale represent approximately 63.5% of shares outstanding as of March 31, 2022 (after giving effect to the issuance of shares upon exercise of outstanding public warrants, private placement warrants, Rigetti assumed warrants and options and settlement of outstanding restricted stock units), and that the sale of shares by the selling securityholders, or the perception in the marketRead in the replyRest of the answer
that the selling securityholders of a large number of shares intend to sell shares, could increase the volatility of the market price of our common stock or result in a significant decline in the public trading price of our common stock.
In light of the significant number of redemptions and the unlikelihood that the company will receive significant proceeds from exercises of the warrants because of the disparity between the exercise price of the warrants and the current trading price of the common stock, expand your discussion of capital resources to address any changes in the company’s liquidity position since the business combination.Rest of the question
If the company is likely to have to seek additional capital, discuss the effect of this offering on the company’s ability to raise additional capital. Risk Factors Additional Risks Related to Ownership of Our Securities Future sales, or the perception of future sales, by us or our stockholders in the public market...,
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on pages 53 and 62-63 of Amendment No. 1.Read in the reply
Risk Factors
Additional Risks Related to Ownership of Our Securities–Future sales, or the perception of future sales, by us or our stockholders in the public market..., page 42
To illustrate the risk that potential sales of shares pursuant to this registration statement could put negative pressure on the trading price, disclose the purchase price of the securities being registered for resale and the percentage that these shares currently represent of the total number of shares outstanding.Rest of the question
Also disclose that even though the current trading price is significantly below the SPAC IPO price, certain private investors may have an incentive to sell because they purchased their shares at prices lower than the public investors.
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on the cover page and pages 45-46 of Amendment No. 1 to disclose the purchase price paid by various selling securityholders for such shares and warrants, the percentage of the total outstanding and reserved shares of common stock the shares being registered for resale represent, and the fact that certain selling securityholders may have an incentive to sell their securities as they purchased their shares at prices lower than the current public trading price of our common stock.Read in the reply
You state on page 42 that “future” resales of the common stock issued in connection with the Merger may cause the market price of your securities to drop significantly. This statement should be updated given that this prospectus is facilitating those sales.Rest of the question
We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement.
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on page 45 of Amendment No. 1.Read in the reply
* * *
We hope the foregoing answers are responsive to your comments. Please direct any questions or comments regarding this correspondence to our counsel, Rupa Briggs, Sarah Sellers and Yoon-jee Kim of Cooley LLP at (212) 479-6525, (212)
479-6370 or (212) 479-6792, respectively.
We note that Ampere is not obligated to make the additional $5 million payment for the second tranche of 500,000 shares if Ampere's capital stock is not listed by the second anniversary of the warrant subscription agreement. Generally, securities issued in a private transaction may not be registered for resale until after the private placement is completed.Rest of the question
In this regard, we note that Ampere is not irrevocably bound to purchase the subject securities because whether Ampere chooses to list its capital stock is a condition within Ampere's control. Please refer to Question 134.01 of our Securities Act Sections Compliance and Disclosure Interpretations for guidance, and provide us with your analysis of how the registration of these shares is appropriate.
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure throughout Amendment No. 1 to remove references to the second tranche of 500,000 shares issuable pursuant to the Ampere Warrant. Accordingly, only the first tranche of 500,000 shares of common stock that were previously issued to Ampere upon its exercise of the vested portion of the Ampere Warrant is being registered for resale in Amendment No. 1.Read in the reply
Revise to identify the natural person or persons who exercise the voting and/or dispositive powers with respect to the securities owned by Ampere Computing LLC. Exhibits
The Company respectfully acknowledges theRead in the reply
Staff’s comment and has revised page 144 of Amendment No. 1 to identify the natural person who exercises the voting and/or dispositive powers with respect to the securities owned by Ampere.
Please file your collaboration agreement with Ampere and revise your prospectus to summarize the material terms of this agreement. See Item 601(b)(10)(ii)(A) of Regulation S-K.
The Company acknowledges the Staff’s comment and respectfully advises the Staff that the Company does not believe it is required to file the collaboration agreement with Ampere under Item 601(b)(10) of Regulation S-K or to disclose the material terms of the collaboration agreement since the collaboration agreement is a contract entered into in the ordinary course of business, is not material to the Company, and is immaterial in amount and significance to the Company.Read in the reply
Item 601(b)(10)(ii) of Regulation S-K states that “if the contract is such as ordinarily accompanies the kind of businessRest of the answer
conducted by the registrant and its subsidiaries, it will be deemed to have been made in the ordinary course of business and need not be filed unless it falls within one or more specified categories, in which case it shall be filed except where immaterial in amount or significance”. Subsection (A) of such Item, which refers to “any contract to which directors, officers, promoters, voting trustees, security holders named in the registration statement or report” is one of the specified categories of contracts required to be filed “except where immaterial in amount or significance”.
The Company respectfully advises the Staff that it believes the collaboration agreement with Ampere does not require filing under Item 601(b)(10)(ii) of Regulation S-K because the collaboration agreement is (i) the kind of contract that ordinarily accompanies the Company’s business and is
(ii) immaterial in amount and significance to the Company as the agreement contains customary terms relating to how the parties plan to work together to identify and develop potential use cases for their products and technologies. The Company has entered into, and expects to enter into from time to time as part of its routine and ordinary operations, numerous collaboration agreements similar to the collaboration agreement with Ampere.
The Company does not believe that additional disclosure concerning the collaboration agreement, through the filing of the agreement as an exhibit to the Registration Statement or otherwise, would provide meaningful disclosure to investors. For the reasons described above, the Company respectfully submits to the Staff that the collaboration agreement is thus not required to be filed under Item 601(b)(10)(ii)(A) of Regulation S-K, nor described at this time.
* *
*
We hope the foregoing answers are responsive to your comments. Please direct any questions or comments regarding this correspondence to our counsel, Rupa Briggs and Sarah Sellers of Cooley LLP at (212) 479-6525 and (212)
479-6370, respectively.